MetLife Investment Management’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $904K | Hold |
64,485
| – | – | 0.01% | 1369 |
|
|
2025
Q1 | $1.01M | Sell |
64,485
-986
| -2% | -$15.4K | 0.01% | 1359 |
|
|
2024
Q4 | $912K | Buy |
65,471
+3,813
| +6% | +$53.1K | ﹤0.01% | 1461 |
|
|
2024
Q3 | $573K | Hold |
61,658
| – | – | ﹤0.01% | 1710 |
|
|
2024
Q2 | $573K | Buy |
61,658
+17,857
| +41% | +$166K | ﹤0.01% | 1650 |
|
|
2024
Q1 | $434K | Hold |
43,801
| – | – | ﹤0.01% | 1753 |
|
|
2023
Q4 | $141K | Buy |
43,801
+16,598
| +61% | +$53.6K | ﹤0.01% | 2428 |
|
|
2023
Q3 | $144K | Hold |
27,203
| – | – | ﹤0.01% | 2386 |
|
|
2023
Q2 | $259K | Buy |
27,203
+5,456
| +25% | +$52K | ﹤0.01% | 2116 |
|
|
2023
Q1 | $239K | Hold |
21,747
| – | – | ﹤0.01% | 2112 |
|
|
2022
Q4 | $322K | Hold |
21,747
| – | – | ﹤0.01% | 1925 |
|
|
2022
Q3 | $416K | Buy |
21,747
+5,029
| +30% | +$96.1K | ﹤0.01% | 1766 |
|
|
2022
Q2 | $356K | Hold |
16,718
| – | – | ﹤0.01% | 1899 |
|
|
2022
Q1 | $322K | Buy |
16,718
+6,170
| +58% | +$119K | ﹤0.01% | 2058 |
|
|
2021
Q4 | $219K | Hold |
10,548
| – | – | ﹤0.01% | 1997 |
|
|
2021
Q3 | $252K | Hold |
10,548
| – | – | ﹤0.01% | 1942 |
|
|
2021
Q2 | $288K | Buy |
10,548
+2,304
| +28% | +$62.9K | ﹤0.01% | 1921 |
|
|
2021
Q1 | $238K | Hold |
8,244
| – | – | ﹤0.01% | 1958 |
|
|
2020
Q4 | $232K | Hold |
8,244
| – | – | ﹤0.01% | 1901 |
|
|
2020
Q3 | $242K | Buy |
8,244
+2,902
| +54% | +$85K | ﹤0.01% | 1747 |
|
|
2020
Q2 | $162K | Hold |
5,342
| – | – | ﹤0.01% | 2021 |
|
|
2020
Q1 | $159K | Buy |
+5,342
| New | +$159K | ﹤0.01% | 1818 |
|